News

WellDyne executives David Skomo, RPh, and Nick Page told PBMI Annual Conference attendees that matching communication channels and messages with patient preference is the way to engage patients and increase adherence.

Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.

High hopes for COVID-19 vaccine for children before the end of the year, Breakthrough Designation for Jardiance, thumbs down on an EUA for cytokine storm therapy and no decision yet on Juul's vaping products.

Briana Contreras of MHE met Stephanie Mercado, CEO and Executive Director of NAHQ (National Association for Healthcare Quality) for this week's episode of Tuning In to the C-Suite. The two discussed NAHQ’s mission to improve healthcare quality and what improvements, as well as shortcomings have been made. She also shared what steps need to be taken in healthcare as a whole to continue improving the quality of care.

Prices in American healthcare are difficult to nail down because they are obscured by secret negotiations between payers and providers and, in the case of drugs, pharmaceutical manufacturers. But that is beginning to change.

For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands.

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.